drugset / Trial / NCT05631626
Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.
RandomizedParallel-groupDouble-blindTreatment
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in adults with ADHD in a laboratory classroom setting.
Timeline
- Start
- 2022-12-29
- Primary completion
- 2023-06-13
- Completion
- 2023-06-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CTx-1301 | Unknown | 25 mg | — |
| Comparator | CTx-1301 | Unknown | 37.5 mg | — |
| Comparator | CTx-1301 | Unknown | 50 mg | — |